Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate)

被引：0
|
作者：
Mersiades, Antony [1 ]
Pavlakis, Nick [2 ]
Kao, Steven [3 ]
John, Tom [4 ]
Lee, Chee Khoon [1 ,5 ]
Dawson, Sarah-Jane [6 ]
Wong, Stephen [6 ]
Tan, Lavinia [6 ]
Yip, Sonia [1 ]
Brown, Chris [1 ]
Livingstone, Ann [1 ]
Cheung, Yvonne [1 ]
Jurkovic, Hannora [1 ]
Stockler, Martin [1 ]
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[2] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia
[3] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[4] Olivia Newton John Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[5] St George Hosp, Dept Med Oncol, Sydney, NSW, Australia
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页码：199 / 200
页数：2
相关论文
共 50 条
  • [31] Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
    Peng, Da
    Shan, Dongfeng
    Dai, Chengcheng
    Li, Jie
    Wang, Zifan
    Huang, Ziyi
    Peng, Rui
    Zhao, Peng
    Ma, Xuezhen
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2033 - 2039
  • [32] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [33] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Sha Liu
    Tao Pan
    Ming-Kun Wang
    Jie Wang
    Shuang Zhang
    Ping Zhou
    Clinical Drug Investigation, 2022, 42 : 459 - 464
  • [34] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Liu, Sha
    Pan, Tao
    Wang, Ming-Kun
    Wang, Jie
    Zhang, Shuang
    Zhou, Ping
    CLINICAL DRUG INVESTIGATION, 2022, 42 (05) : 459 - 464
  • [35] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [36] A Case of a Patient Harboring an EGFR-T790M Mutation Positive in Squamous Cell Lung Cancer
    Runciman, T.
    Aliaga, C.
    Carracedo Gonzales, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1025 - S1026
  • [37] Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
    Kim, Hye Sook
    Lim, Kun Young
    Lee, Soo-Hyun
    Kim, Hyae Young
    Lee, Youngjoo
    Han, Ji-Youn
    CANCER MEDICINE, 2023, 12 (11): : 12285 - 12298
  • [38] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [39] A Case of a Patient Harboring an EGFR-T790M Mutation Positive in Squamous Cell Lung Cancer
    Runciman, T.
    Carracedo, C.
    Aliaga, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S179 - S179
  • [40] The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
    Gil, Hyun-Il
    Um, Sang-Won
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 153 - 155
12345